PA
NCNO icon

PharVision Advisers’s nCino NCNO Stock Holding History

PharVision Advisers’s Portfolio NCNO Stock Details NCNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,195
Closed -$276K – 900
2025
Q3 		$276K Buy
+10,195
New +$298K 0.16% 275

Other funds holding NCNO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
HMI Capital Management San Francisco, California $754M AUM 23.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
LPP
Long Path Partners Stamford, Connecticut $220M AUM 25.96% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

PharVision Advisers's NCNO Position: Q4 2025 in Review

PharVision Advisers sold out of nCino (NCNO) in Q4 2025, closing a stake of 10,195 shares — an estimated $276K sold.

PharVision Advisers first reported a position in NCNO in Q3 2025 and held it in 1 quarter. The position peaked at $276K in Q3 2025. 295 funds tracked by Wall St. Rank hold NCNO as of Q4 2025.

  • PharVision Advisers reported no remaining nCino position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 10,195 nCino shares in Q4 2025, an estimated $276K.
  • PharVision Advisers first reported a position in nCino in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's nCino position peaked at $276K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held nCino as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.